Chemomab reports 2022 Annual Meeting vote results; all proposals pass

Chemomab Therapeutics Ltd.

Proposal 1: re-elect Dr. Nissim Darvish as Class I director received 84,055,680 FOR, 591,060 AGAINST.
Proposal 2: approve amendment to compensation of Dr. Adi Mor (CSO) passed with 83,840,260 FOR.
Proposal 4: reappoint Somekh Chaikin (KPMG) as auditor approved with 84,152,640 FOR.
Proposal 3 (equity grants to directors) was withdrawn prior to the meeting.
Total shares represented: 84,756,220 ordinary (37.16% of outstanding).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.